Article Text
Featured correspondence
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
Statistics from Altmetric.com
To the editor: It is very disappointing to read a largely uncritical regurgitation of opinion on the clinical use of thiazolidinediones in type 2 diabetes.1
Far too often, cardiology-based opinions are being published without proper reference to the importance of glycaemic control …
Footnotes
Competing interests: Declared. The author has received honoraria from GSK, Takeda and Lilly pharmaceuticals for speaker engagements and attendance at advisory board meetings.
Linked Articles
- Featured correspondence